United Therapeutics Corporation APIC, Share-based Payment Arrangement, Increase for Cost Recognition
United Therapeutics Corporation (UTHR) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $43.40 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-05
- United Therapeutics Corporation apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $43.40M, a 14.81% increase year-over-year.
- United Therapeutics Corporation apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $33.90M, a 3.99% increase year-over-year.
- United Therapeutics Corporation apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $39.00M, a 47.73% increase year-over-year.
- United Therapeutics Corporation apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $39.10M, a 9.22% increase year-over-year.
- United Therapeutics Corporation apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $148.50M, a 32.95% increase from fiscal 2024.
- United Therapeutics Corporation apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $111.70M, a 60.03% increase from fiscal 2023.
- United Therapeutics Corporation apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $69.80M, a 16.14% increase from fiscal 2022.
- United Therapeutics Corporation apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $60.10M, a 15.80% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $43.40M 10-Q · filed 2026-08-05 | $77.30M 10-Q · filed 2026-08-05 | $116.30M derived: sum of 3 quarters · filed 2026-08-05 | $155.40M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $33.90M 10-Q · filed 2026-05-06 | $72.90M derived: sum of 2 quarters · filed 2026-05-06 | $112.00M derived: sum of 3 quarters · filed 2026-05-06 | $149.80M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $39.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $78.10M derived: sum of 2 quarters · filed 2026-02-25 | $115.90M derived: sum of 3 quarters · filed 2026-08-05 | $148.50M 10-K · filed 2026-02-25 | |
| 2025-09-30 | $39.10M 10-Q · filed 2025-10-29 | $76.90M derived: sum of 2 quarters · filed 2026-08-05 | $109.50M 10-Q · filed 2025-10-29 | $135.90M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $37.80M 10-Q · filed 2026-08-05 | $70.40M 10-Q · filed 2026-08-05 | $96.80M derived: sum of 3 quarters · filed 2026-08-05 | $132.60M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $32.60M 10-Q · filed 2026-05-06 | $59.00M derived: sum of 2 quarters · filed 2026-05-06 | $94.80M derived: sum of 3 quarters · filed 2026-05-06 | $122.60M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | $26.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $62.20M derived: sum of 2 quarters · filed 2026-02-25 | $90.00M derived: sum of 3 quarters · filed 2026-02-25 | $111.70M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $35.80M 10-Q · filed 2025-10-29 | $63.60M derived: sum of 2 quarters · filed 2025-10-29 | $85.30M 10-Q · filed 2025-10-29 | $102.80M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2024-06-30 | $27.80M 10-Q · filed 2025-07-30 | $49.50M 10-Q · filed 2025-07-30 | $67.00M derived: sum of 3 quarters · filed 2026-02-25 | $86.00M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2024-03-31 | $21.70M 10-Q · filed 2025-04-30 | $39.20M derived: sum of 2 quarters · filed 2026-02-25 | $58.20M derived: sum of 3 quarters · filed 2026-02-25 | $73.90M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2023-12-31 | $17.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $36.50M derived: sum of 2 quarters · filed 2026-02-25 | $52.20M derived: sum of 3 quarters · filed 2026-02-25 | $69.80M 10-K · filed 2026-02-25 | |
| 2023-09-30 | $19.00M 10-Q · filed 2024-10-30 | $34.70M derived: sum of 2 quarters · filed 2024-10-30 | $52.30M 10-Q · filed 2024-10-30 | $70.60M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2023-06-30 | $15.70M 10-Q · filed 2024-07-31 | $33.30M 10-Q · filed 2024-07-31 | $51.60M derived: sum of 3 quarters · filed 2025-02-26 | $67.70M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2023-03-31 | $17.60M 10-Q · filed 2024-05-01 | $35.90M derived: sum of 2 quarters · filed 2025-02-26 | $52.00M derived: sum of 3 quarters · filed 2025-02-26 | $65.40M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2022-12-31 | $18.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $34.40M derived: sum of 2 quarters · filed 2025-02-26 | $47.80M derived: sum of 3 quarters · filed 2025-02-26 | $60.10M 10-K · filed 2025-02-26 | |
| 2022-09-30 | $16.10M 10-Q · filed 2023-11-01 | $29.50M derived: sum of 2 quarters · filed 2023-11-01 | $41.80M 10-Q · filed 2023-11-01 | $54.20M derived: sum of 4 quarters · filed 2024-02-21 | |
| 2022-06-30 | $13.40M 10-Q · filed 2023-08-02 | $25.70M 10-Q · filed 2023-08-02 | $38.10M derived: sum of 3 quarters · filed 2024-02-21 | $50.50M derived: sum of 4 quarters · filed 2024-02-21 | |
| 2022-03-31 | $12.30M 10-Q · filed 2023-05-03 | $24.70M derived: sum of 2 quarters · filed 2024-02-21 | $37.10M derived: sum of 3 quarters · filed 2024-02-21 | $49.80M derived: sum of 4 quarters · filed 2024-02-21 | |
| 2021-12-31 | $12.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $24.80M derived: sum of 2 quarters · filed 2024-02-21 | $37.50M derived: sum of 3 quarters · filed 2024-02-21 | $51.90M 10-K · filed 2024-02-21 | |
| 2021-09-30 | $12.40M 10-Q · filed 2022-11-02 | $25.10M derived: sum of 2 quarters · filed 2022-11-02 | $39.50M 10-Q · filed 2022-11-02 | $54.70M derived: sum of 4 quarters · filed 2023-02-22 | |
| 2021-06-30 | $12.70M 10-Q · filed 2022-08-03 | $27.10M 10-Q · filed 2022-08-03 | $42.30M derived: sum of 3 quarters · filed 2023-02-22 | $57.30M derived: sum of 4 quarters · filed 2023-02-22 | |
| 2021-03-31 | $14.40M 10-Q · filed 2022-05-04 | $29.60M derived: sum of 2 quarters · filed 2023-02-22 | $44.60M derived: sum of 3 quarters · filed 2023-02-22 | $59.70M derived: sum of 4 quarters · filed 2023-02-22 | |
| 2020-12-31 | $15.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $30.20M derived: sum of 2 quarters · filed 2023-02-22 | $45.30M derived: sum of 3 quarters · filed 2023-02-22 | $66.00M 10-K · filed 2023-02-22 | |
| 2020-09-30 | $15.00M 10-Q · filed 2021-11-03 | $30.10M derived: sum of 2 quarters · filed 2021-11-03 | $50.80M 10-Q · filed 2021-11-03 | $72.90M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2020-06-30 | $15.10M 10-Q · filed 2021-08-04 | $35.80M 10-Q · filed 2021-08-04 | $57.90M derived: sum of 3 quarters · filed 2022-02-24 | $80.40M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2020-03-31 | $20.70M 10-Q · filed 2021-05-05 | $42.80M derived: sum of 2 quarters · filed 2022-02-24 | $65.30M derived: sum of 3 quarters · filed 2022-02-24 | $87.50M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2019-12-31 | $22.10M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $44.60M derived: sum of 2 quarters · filed 2022-02-24 | $66.80M derived: sum of 3 quarters · filed 2022-02-24 | $85.10M 10-K · filed 2022-02-24 | |
| 2019-09-30 | $22.50M 10-Q · filed 2020-10-28 | $44.70M derived: sum of 2 quarters · filed 2020-10-28 | $63.00M 10-Q · filed 2020-10-28 | $79.20M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2019-06-30 | $22.20M 10-Q · filed 2020-07-29 | $40.50M 10-Q · filed 2020-07-29 | $56.70M derived: sum of 3 quarters · filed 2021-02-24 | $75.30M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2019-03-31 | $18.30M 10-Q · filed 2020-04-29 | $34.50M derived: sum of 2 quarters · filed 2021-02-24 | $53.10M derived: sum of 3 quarters · filed 2021-02-24 | $70.90M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2018-12-31 | $16.20M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $34.80M derived: sum of 2 quarters · filed 2021-02-24 | $52.60M derived: sum of 3 quarters · filed 2021-02-24 | $66.50M 10-K · filed 2021-02-24 | |
| 2018-09-30 | $18.60M 10-Q · filed 2019-10-30 | $36.40M derived: sum of 2 quarters · filed 2019-10-30 | $50.30M 10-Q · filed 2019-10-30 | ||
| 2018-06-30 | $17.80M 10-Q · filed 2019-07-31 | $31.70M 10-Q · filed 2019-07-31 | |||
| 2018-03-31 | $13.90M 10-Q · filed 2019-05-01 | ||||
| 2017-12-31 | $46.40M 10-K · filed 2020-02-26 | ||||
| 2016-12-31 | $27.30M 10-K · filed 2019-02-27 | ||||
| 2015-12-31 | $6.10M 10-K · filed 2018-02-21 | $6.08M 10-K · filed 2016-02-25 | |||
| 2014-12-31 | $30.60M 10-K · filed 2017-02-22 | $30.57M 10-K · filed 2015-02-24 | |||
| 2013-12-31 | $36.90M 10-K · filed 2016-02-25 | ||||
| 2012-12-31 | $3.26M 10-K · filed 2015-02-24 | ||||
| 2011-12-31 | $527.00K 10-K · filed 2014-02-25 | ||||
| 2010-12-31 | $22.65M 10-K · filed 2013-02-26 | ||||
| 2009-12-31 | $40.14M 10-K · filed 2012-02-28 | ||||
| 2008-12-31 | $28.47M 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |